NCT06417047

Brief Summary

It was aimed to examine the effect of the hand holding method applied during intramuscular injection on pain and anxiety.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
104

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 12, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 16, 2024

Completed
2 months until next milestone

Study Start

First participant enrolled

July 20, 2024

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 10, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 10, 2024

Completed
Last Updated

August 26, 2025

Status Verified

August 1, 2025

Enrollment Period

2 months

First QC Date

May 12, 2024

Last Update Submit

August 19, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Numerical Pain Scale

    A score of "0" indicated the lowest pain, and a score of "10" indicated the highest pain.

    It will be filled within 1 minute after the intramuscular injection is completed.

Secondary Outcomes (1)

  • State Anxiety Scale

    It will be filled immediately before the intramuscular injection and within 1 minute after the procedure is completed.

Study Arms (2)

Hand Holding Group

EXPERIMENTAL

In the experimental group, hand holding will be done by the researcher, and intramuscular injection will be done by the clinical nurse. All intramuscular injections will be performed by a single nurse and the ventrogluteal region will be used as the injection site. Patients will first fill out the Voluntary Information and Consent Form, and then the Descriptive Characteristics Form and State Anxiety Scale. After the injection site is evaluated, the researcher will hold the patient's hand, the nurse will enter the tissue at a 90-degree angle and administer the drug slowly (1 ml/10 seconds). After removing the needle from the tissue, the nurse will apply pressure with dry cotton, and then the researcher will stop holding the patient's hand. After the procedure, the Numerical Pain Scale and State Anxiety Scale will be filled in within 1 minute.

Other: Hand Holding

Control Group

NO INTERVENTION

In the control group, intramuscular injection will be performed by the clinic nurse. All intramuscular injections will be performed by a single nurse and the ventrogluteal region will be used as the injection site. Patients will first fill out the Voluntary Information and Consent Form, and then the Descriptive Characteristics Form and State Anxiety Scale. After the injection site is assessed, the nurse will enter the tissue at a 90-degree angle and administer the medication slowly (1 ml/10 seconds). After removing the needle from the tissue, the nurse will apply pressure with dry cotton. After the procedure, the Numerical Pain Scale and State Anxiety Scale will be filled in within 1 minute.

Interventions

During the intramuscular injection, the aim is to draw the patients' attention elsewhere by holding their hand.

Hand Holding Group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Having vitamin B 12 1000 mcg/ml (1 ml ampoule) intramuscular treatment,
  • Being literate,
  • Are between the ages of 18-65,
  • No visual, hearing, sensory or motor loss or cognitive impairment,
  • Not using centrally or peripherally acting analgesics or sedatives,
  • There is no scar tissue, incision, lipodystrophy or signs of infection on the skin of the injection area,
  • Having a body mass index between 18.5 and 29.5,
  • Injected into the ventrogluteal area,
  • Individuals who agree to participate in the research will be included.

You may not qualify if:

  • Those with chronic pain,
  • Having a psychiatric disorder,
  • Foreign nationals,
  • Patients with contact-communicable diseases will be excluded from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Necmettin Erbakan University

Konya, Meram, Turkey (Türkiye)

Location

MeSH Terms

Conditions

PainAnxiety Disorders

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsMental Disorders

Study Officials

  • Serpil SU

    Necmettin Erbakan University

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
Double (Participant, Outcomes Assessor) The patients will be informed about the study and their consent will be obtained without explaining which group they are in. Since the researcher manages the implementation process of the study, researcher blinding cannot be done. In addition, it will be ensured that the researcher learns which group the patients are in after the patients accept to participate in the study. Thus, the internal validity of the research will be ensured. At the same time, blind technique will be applied in terms of statistical analysis in the research. The data will be recorded on the computer by the researcher without using the expression of experimental and control groups, and data analysis will be done by another statistician other than the person who made the randomization.
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: Parallel Assignment
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professors

Study Record Dates

First Submitted

May 12, 2024

First Posted

May 16, 2024

Study Start

July 20, 2024

Primary Completion

September 10, 2024

Study Completion

September 10, 2024

Last Updated

August 26, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations